Preferred Stock, Shares Authorized of GT Biopharma, Inc. from Q4 2010 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Summary
GT Biopharma, Inc. quarterly Preferred Stock, Shares Authorized history and change rate from Q4 2010 to Q3 2025.
  • GT Biopharma, Inc. Preferred Stock, Shares Authorized for the quarter ending 30 Sep 2025 was 15M shares, unchanged year-over-year.
Preferred Stock, Shares Authorized, Quarterly (shares)
Preferred Stock, Shares Authorized, YoY Quarterly Change (%)

GT Biopharma, Inc. Quarterly Preferred Stock, Shares Authorized (shares)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 15M 0 0% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 15M 0 0% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 15M 0 0% 31 Mar 2025 10-Q 15 May 2025
Q4 2024 15M 0 0% 31 Dec 2024 10-Q 14 Nov 2025
Q3 2024 15M 0 0% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 15M 0 0% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 15M 0 0% 31 Mar 2024 10-Q 15 May 2024
Q4 2023 15M 0 0% 31 Dec 2023 10-K 21 Feb 2025
Q3 2023 15M 0 0% 30 Sep 2023 10-Q 01 Nov 2023
Q2 2023 15M 0 0% 30 Jun 2023 10-Q 07 Aug 2023
Q1 2023 15M 0 0% 31 Mar 2023 10-Q 15 May 2023
Q4 2022 15M 0 0% 31 Dec 2022 10-K 26 Mar 2024
Q3 2022 15M 0 0% 30 Sep 2022 10-Q 31 Oct 2022
Q2 2022 15M 0 0% 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 15M 0 0% 31 Mar 2022 10-Q 16 May 2022
Q4 2021 15M 0 0% 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 15M 0 0% 30 Sep 2021 10-Q 10 Nov 2021
Q2 2021 15M 0 0% 30 Jun 2021 10-Q/A 29 Dec 2021
Q1 2021 15M 0 0% 31 Mar 2021 10-Q 17 May 2021
Q4 2020 15M 0 0% 31 Dec 2020 10-K 28 Mar 2022
Q3 2020 15M 0 0% 30 Sep 2020 10-Q 13 Nov 2020
Q2 2020 15M 0 0% 30 Jun 2020 10-Q/A 18 Aug 2020
Q1 2020 15M 0 0% 31 Mar 2020 10-Q 15 May 2020
Q4 2019 15M 0 0% 31 Dec 2019 10-K 16 Apr 2021
Q3 2019 15M 0 0% 30 Sep 2019 10-Q 14 Nov 2019
Q2 2019 15M 0 0% 30 Jun 2019 10-Q 14 Aug 2019
Q1 2019 15M 0 0% 31 Mar 2019 10-Q 15 May 2019
Q4 2018 15M 0 0% 31 Dec 2018 10-K 27 Mar 2020
Q3 2018 15M 0 0% 30 Sep 2018 10-Q 14 Nov 2018
Q2 2018 15M 0 0% 30 Jun 2018 10-Q 14 Aug 2018
Q1 2018 15M 0 0% 31 Mar 2018 10-Q 15 May 2018
Q4 2017 15M 0 0% 31 Dec 2017 10-K 29 Mar 2019
Q3 2017 15M 0 0% 30 Sep 2017 10-Q 14 Nov 2017
Q2 2017 15M 0 0% 30 Jun 2017 10-Q 11 Aug 2017
Q1 2017 15M 0 0% 31 Mar 2017 10-Q 28 Apr 2017
Q4 2016 15M 0 0% 31 Dec 2016 10-K 01 Mar 2018
Q3 2016 15M 0 0% 30 Sep 2016 10-Q/A 28 Feb 2018
Q2 2016 15M 0 0% 30 Jun 2016 10-Q/A 28 Feb 2018
Q1 2016 15M 0 0% 31 Mar 2016 10-Q/A 28 Feb 2018
Q4 2015 15M 0 0% 31 Dec 2015 10-K/A 28 Feb 2018
Q3 2015 15M 0 0% 30 Sep 2015 10-Q 13 Nov 2015
Q2 2015 15M 0 0% 30 Jun 2015 10-Q 14 Aug 2015
Q1 2015 15M 0 0% 31 Mar 2015 10-Q 14 May 2015
Q4 2014 15M 0 0% 31 Dec 2014 10-K/A 28 Feb 2018
Q3 2014 15M 0 0% 30 Sep 2014 10-Q 08 Jan 2015
Q2 2014 15M 0 0% 30 Jun 2014 10-Q 08 Jan 2015
Q1 2014 15M 0 0% 31 Mar 2014 10-Q 08 Jan 2015
Q4 2013 15M 0 0% 31 Dec 2013 10-K 31 Mar 2015
Q3 2013 15M 0 0% 30 Sep 2013 10-Q 17 Dec 2014
Q2 2013 15M 0 0% 30 Jun 2013 10-Q 12 Dec 2014
Q1 2013 15M 0 0% 31 Mar 2013 10-Q 10 Dec 2014
Q4 2012 15M 0 0% 31 Dec 2012 10-K 08 Jan 2015
Q3 2012 15M 0 0% 30 Sep 2012 10-Q 21 Nov 2012
Q2 2012 15M 0 0% 30 Jun 2012 10-Q/A 13 Sep 2012
Q1 2012 15M 31 Mar 2012 10-Q 21 May 2012
Q4 2011 15M 0 0% 31 Dec 2011 10-K 18 Nov 2014
Q3 2011 15M 30 Sep 2011 10-Q 21 Nov 2011
Q2 2011 15M 30 Jun 2011 10-Q/A 12 Sep 2011
Q4 2010 15M 31 Dec 2010 10-K 16 Apr 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.